002437.SZ SHZ
Harbin Gloria Pharmaceuticals Co., Ltd
1W: -3.4%
1M: -16.5%
3M: +24.1%
YTD: +4.9%
1Y: +2.8%
3Y: +78.9%
5Y: +43.1%
¥3.65 ($0.54)
+0.18 (+5.19%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$2.8B
-10.4% ▼
5Y CAGR: -15.1%
Total Liabilities
$852M
-40.9% ▼
5Y CAGR: -29.3%
Shareholders Equity
$2.0B
+17.4% ▲
5Y CAGR: +5.1%
Cash & Investments
$512M
-28.0% ▼
5Y CAGR: -17.2%
Total Debt
$2M
-99.7% ▼
5Y CAGR: -76.4%
Net Debt
-$480M
-1248.9% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $895M | $1.5B | $1.2B | $711M | $482M |
| Short-Term Investments | $0 | $0 | $51M | $0 | $30M |
| Cash & ST Investments | $895M | $1.5B | $1.3B | $711M | $512M |
| Net Receivables | $340M | $318M | $237M | $241M | $147M |
| Inventory | $371M | $352M | $214M | $191M | $189M |
| Other Current Assets | $179M | $117M | $77M | $521K | $15M |
| Total Current Assets | $1.8B | $2.2B | $1.8B | $1.2B | $877M |
| Property, Plant & Equip. | $1.3B | $1.2B | $1.1B | $1.1B | $1.0B |
| Goodwill & Intangibles | $766M | $708M | $595M | $569M | $550M |
| Long-Term Investments | $579M | $509M | $408M | $331M | $248M |
| Other Non-Current Assets | $16M | $18M | $102M | $13M | $105M |
| Total Non-Current Assets | $2.7B | $2.5B | $2.3B | $2.0B | $1.9B |
| Total Assets | $4.5B | $4.7B | $4.1B | $3.2B | $2.8B |
| — Liabilities — | |||||
| Accounts Payable | $284M | $270M | $75M | $70M | $60M |
| Short-Term Debt | $1.4B | $1.6B | $1.5B | $676M | $105M |
| Deferred Revenue | $888M | $836M | $83M | $50M | $0 |
| Other Current Liabilities | $16M | $763M | $723M | $617M | -$45M |
| Total Current Liabilities | $2.5B | $2.7B | $2.3B | $1.4B | $823M |
| Long-Term Debt | $11M | $0 | $0 | $0 | $0 |
| Other Non-Current Liab. | -$10M | $825K | $28K | $18M | $1M |
| Total Non-Current Liabilities | $43M | $38M | $34M | $30M | $29M |
| Total Liabilities | $2.6B | $2.7B | $2.4B | $1.4B | $852M |
| — Equity — | |||||
| Common Stock | $2.2B | $2.2B | $2.2B | $2.2B | $2.3B |
| Retained Earnings | -$874M | -$1.1B | -$1.0B | -$914M | -$681M |
| Accumulated OCI | $107M | $367M | $64M | -$1M | -$3M |
| Total Stockholders Equity | $1.8B | $1.9B | $1.6B | $1.7B | $2.0B |
| Total Liabilities & Equity | $4.5B | $4.7B | $4.1B | $3.2B | $2.8B |
| — Key Metrics — | |||||
| Total Debt | $1.4B | $1.6B | $1.5B | $676M | $2M |
| Net Debt | $457M | $62M | $217M | -$36M | -$480M |
| Total Investments | $579M | $509M | $458M | $331M | $278M |